This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Biohaven Ltd. Securities Class Action
Business class action lawsuit

Biohaven Ltd. Securities Class Action

Analysis based on 7 articles · First reported Aug 15, 2025 · Last updated Sep 09, 2025

Sentiment
-20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Biohaven Pharmaceutical Holding Company could lead to significant financial liabilities for the company, potentially impacting its stock price and investor confidence. For investors who purchased Biohaven Pharmaceutical Holding Company securities during the Class Period, there is a potential for compensation through the lawsuit.

Pharmaceuticals Legal Services
Event Summary

Rosen Law Firm is actively reminding investors of the September 12, 2025, lead plaintiff deadline for a securities class action lawsuit against Biohaven Pharmaceutical Holding Company The lawsuit alleges that Biohaven Pharmaceutical Holding Company made false and misleading statements to investors between March 24, 2023, and May 14, 2025. Specifically, the company is accused of overstating the regulatory prospects of its drug troriluzole for spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder. These alleged misrepresentations, once revealed, are claimed to have negatively impacted Biohaven Pharmaceutical Holding Company's business and financial condition, causing damages to investors. Philip Kim and Lawrence Rosen of Rosen Law Firm are leading the efforts to encourage affected investors to join the class action.

Entities Involved
stock
Biohaven Pharmaceutical Holding Company
Biohaven Pharmaceutical Holding Company is the defendant in a securities class action lawsuit, accused of making false and misleading statements regarding its drug prospects.
Importance 100.0 Sentiment -40.0
priv
Rosen Law Firm
Rosen Law Firm is reminding investors of the lead plaintiff deadline in a securities class action lawsuit against Biohaven Pharmaceutical Holding Company
Importance 80.0 Sentiment 20.0
per
Philip Kim
Philip Kim, Esq. is a contact person at Rosen Law Firm for investors interested in joining the class action.
Importance 30.0 Sentiment 10.0
per
Lawrence Rosen
Lawrence Rosen, Esq. is a founding partner of Rosen Law Firm, which is representing investors in the class action.
Importance 30.0 Sentiment 10.0
Relationships
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.